States

The Opioid Prevention Campaign is a public health media campaign to help prevent adolescent substance use. The stress and uncertainty that surrounds COVID-19 has resulted in a rise in drug and alcohol use. Take action today to prevent opioid use disorder among teens and adolescents.

This Opioid Prevention Campaign toolkit translates the science of prevention into simple strategies parents and caregivers can incorporate into busy daily lives -- to do what we can to protect our kids from developing an addiction later in life.

The Centers for Medicare and Medicaid Services is responding to the opioid epidemic by promoting safe and responsible pain management, making sure patients can access treatment for opioid use disorder, and using data to target prevention and treatment.

Starting January 1, 2020, under the Calendar Year (CY) 2020 Physician Fee Schedule final rule the Centers for Medicare & Medicaid Services will pay Opioid Treatment Programs through bundled payments for opioid use disorder treatment services in an episode of care provided to people with Medicare Part B (Medical Insurance).

In the Calender Year 2020 Physician Fee Schedule final rule, the Centers for Medicare and Medicaid Services included new coding and payment for a monthly bundle of services for the treatment of opioid use disorder that includes overall management, care coordination, individual and group psychotherapy, substance use counseling, and add-on code for additional counseling. This is a way for clinicians to bill for a group of services in the office setting similar to the services covered under the Opioid Treatment Program benefit for clinics.

The U.S. Agency for Healthcare Research and Quality, on behalf of the U.S. Department of Health and Human Services, commissioned a rapid evidence review on the effectiveness of interventions to promote a broader understanding of the published literature on medication-assisted treatment retention among adults with opioid use disorder.

SAMHSA recognizes the challenges posed by the current COVID-19 situation and is providing the following guidance on the provision of methadone and buprenorphine for the treatment of Opioid Use Disorder in the COVID-19 emergency for Opioid Treatment Programs.

This guide supports health care providers, systems, and communities seeking to prevent substance misuse among young adults. It describes relevant research findings, examines emerging and best practices, identifies knowledge gaps and implementation challen

This report presents feasible, evidence-based practices that health systems can take to improve patient engagement and safety during the transition from inpatient to outpatient care.

This webinar explored: - The demographics and health care needs of the LGBTQ+ population - Barriers to high quality health care for LGBTQ+ people and proposed solutions - A toolkit designed to train medical school students and current providers on clinica